Table 1

Study inclusion and exclusion criteria

Inclusion criteria
Study group: chemotherapy-treated pregnant patients with cancerControl group 1: chemotherapy-untreated pregnant patients with cancerControl group 2: healthy pregnant women

  • Histologically proven cancer during pregnancy (any type and stage)

  • Treatment during the second and/or third trimester of pregnancy with one or a combination of the following chemotherapeutic agents: cyclophosphamide, anthracyclines, taxanes, platinum derivates

  • Gestational age (GA) at birth ≥24 weeks

  • Histologically proven cancer during pregnancy (any type and stage)

  • No treatment during pregnancy or surgery only (subgroup 1)

  • Radiotherapy and/or systemic treatment (other than chemotherapy) during pregnancy (subgroup 2)*

  • GA at birth ≥24 weeks

  • Matched for maternal age, gestational age at birth and infant sex with chemotherapy-treated group

  • GA at birth ≥24 weeks

Exclusion criteria

  • GA at birth <24 weeks (miscarriage or termination of pregnancy)

  • Inability to give informed consent, for example, due to mental disabilities

  • Any comorbidity that is associated with an increased micronucleus frequency, such as hypertensive disorders, preeclampsia, (gestational) diabetes, renal or cardiac pathology

  • *Subgroups 1 and 2 will be analysed as separate control groups.